Compare Stocks › ABBV vs MRNA
AbbVie Inc. (ABBV) vs Moderna, Inc. (MRNA)
ABBV
AbbVie Inc.
$206.60
VS
MRNA
Moderna, Inc.
$45.37
Rewards
ABBV
- ★AbbVie Inc. has maintained ROIC above 10% for 4 consecutive years, suggesting solid business economics.
- ★Gross margin of 72.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
- ★AbbVie Inc. scores 83/100 on the Economic Moat Score (Wide Moat), with reinvestment efficiency as the strongest competitive dimension.
MRNA
Risks
ABBV
- ⚠Buybacks have been poorly timed — 3 out of 4 years involved repurchases at relatively expensive valuations.
- ⚠Trailing P/E of 100.8x is 61% above the historical average of 62.5x — the stock trades at a premium to its own history.
- ⚠Insiders have sold $10.7M worth of stock in the past 3 months — significant insider liquidation.
MRNA
- ⚠ROIC has declined by 61.0 percentage points over the observed period, which may signal competitive erosion.
- ⚠Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
- ⚠Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.
Key Valuation Metrics
Learn more →ABBV
MRNA
Valuation
N/A
Free Cash Flow
$-20.00M
N/A
FCF Yield
-0.11%
100.78
Trailing P/E
N/A
12.77
Forward P/E
-9.86
Quality & Moat
22.90%
ROIC
-26.47%
N/A
ROE
-38.09%
72.03%
Gross Margin
-69.89%
0.57
PEG Ratio
N/A
Balance Sheet Safety
N/A
Debt / Equity
0.18
N/A
Interest Coverage
N/A
2.10
Net Debt / EBITDA
N/A
3.35%
Dividend Yield
N/A
ABBV: 2Ties: 1MRNA: 1
ABBVMRNA
Historical Fundamentals
Learn more →ABBV
Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation.
MRNA
Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation.
Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation.
$1 Retained Earnings Test
Learn more →ABBV
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-19.85B
Δ Market Cap
+$118.02B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
MRNA
N/A
Net losses over 3 years — test not applicable
Company had negative cumulative retained earnings
Σ Retained
$-11.10B
Δ Market Cap
$-57.53B
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
> $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
Discounted Cash Flow (DCF) Analysis
Learn more →ABBV
481.9% Overvalued
Price is 481.9% above estimated fair value
Current Price: $206.60
Strongly undervalued
Strongly overvalued
Fair Value: $35.50
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
MRNA
633.5% Overvalued
Price is 633.5% above estimated fair value
Current Price: $45.37
Strongly undervalued
Strongly overvalued
Fair Value: $6.19
Strongly undervalued
Undervalued
Fairly valued
Overvalued
Strongly overvalued
Reverse DCF — Market-Implied Growth
Learn more →ABBV
Requires positive FCF to compute implied growth rate.
MRNA
Requires positive FCF to compute implied growth rate.
Economic Moat Score
Learn more →ABBV
83/100
Wide Moat
70+ Wide · 40-69 Narrow · <40 None
Wide moat with strength across all dimensions. Reinvestment Efficiency is the standout factor.
Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
MRNA
17/100
No Moat
70+ Wide · 40-69 Narrow · <40 None
No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.
Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
Forensic Accounting
Learn more →ABBV
-2.86
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone
M-Score Trend
Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
MRNA
-3.72
Unlikely Manipulator
Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone
M-Score Trend
Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
Ownership Breakdown
Learn more →ABBV
Insiders 0.1%Institutions 76.5%Retail & Other 23.4%
No. of Institutional Holders5,052
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
MRNA
Insiders 7.3%Institutions 76.9%Retail & Other 15.8%
No. of Institutional Holders992
High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.
Insider Buying Activity
Learn more →ABBV
0
Buys (3M)
0
Buys (12M)
No open market insider purchases found.
Open market purchases · includes direct & indirect ownership · excludes option exercises
MRNA
0
Buys (3M)
0
Buys (12M)
BANCEL STEPHANE J
Chief Executive Officer
$5.00M
@ $31.22 · 2025-03-03
SAGAN PAUL L
Director
$1.00M
@ $31.76 · 2025-03-03
Open market purchases · includes direct & indirect ownership · excludes option exercises
Open market purchases · includes direct & indirect ownership · excludes option exercises.
Insider Selling Activity
Learn more →ABBV
3
Sells (3M)
5
Sells (12M)
Total value (12M): $21.79M
PURDUE DAVID R.
Officer
$1.22M
@ $233.56 · 2026-03-04
SIATIS PERRY C.
General Counsel
$4.38M
@ $234.39 · 2026-03-02
SIATIS PERRY C.
General Counsel
$5.15M
@ $230.00 · 2026-02-25
SALEKI-GERHARDT AZITA
Chief Operating Officer
$8.41M
@ $198.42 · 2025-08-12
DONOGHOE NICHOLAS
Officer
$2.64M
@ $198.51 · 2025-08-05
STEWART JEFFREY RYAN
Officer
$12.36M
@ $210.08 · 2025-03-31
REENTS SCOTT T.
Chief Financial Officer
$3.75M
@ $212.34 · 2025-03-14
GONZALEZ RICHARD A
Director
$20.26M
@ $205.45 · 2025-03-03
SIATIS PERRY C.
General Counsel
$5.82M
@ $208.69 · 2025-03-03
RICHMOND TIMOTHY J
Officer
$4.47M
@ $210.45 · 2025-03-03
BUCKBEE KEVIN K
Officer
$3.85M
@ $203.41 · 2025-02-26
RICHMOND TIMOTHY J
Officer
$6.07M
@ $202.90 · 2025-02-26
SIATIS PERRY C.
General Counsel
$1.14M
@ $197.90 · 2025-02-20
BUCKBEE KEVIN K
Officer
$310,032
@ $172.24 · 2024-12-16
GONZALEZ RICHARD A
Officer and Director
$12.40M
@ $186.52 · 2024-08-05
GONZALEZ RICHARD A
Officer and Director
$49.50M
@ $175.00 · 2024-07-17
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
MRNA
2
Sells (3M)
4
Sells (12M)
Total value (12M): $8.56M
KLINGER SHANNON THYME
Officer
$726,047
@ $52.29 · 2026-03-02
HOGE STEPHEN
President
$7.81M
@ $48.84 · 2026-02-23
HUSSAIN SHAH ABBAS
Director
$13,910
@ $27.60 · 2025-12-09
HUSSAIN SHAH ABBAS
Director
$8,736
@ $28.00 · 2025-06-11
KLINGER SHANNON THYME
Officer
$23,637
@ $44.68 · 2024-12-09
KLINGER SHANNON THYME
Officer
$4,849
@ $43.29 · 2024-12-03
HOGE STEPHEN
President
$13,595
@ $43.30 · 2024-12-03
KLINGER SHANNON THYME
Officer
$60,675
@ $42.79 · 2024-11-29
MOCK JAMES M
Chief Financial Officer
$60,761
@ $42.79 · 2024-11-29
HOGE STEPHEN
President
$12,452
@ $42.79 · 2024-11-29
HOGE STEPHEN
President
$12,771
@ $46.10 · 2024-11-11
MOCK JAMES M
Chief Financial Officer
$42,986
@ $60.12 · 2024-10-07
KLINGER SHANNON THYME
Officer
$40,539
@ $73.57 · 2024-09-09
HOGE STEPHEN
President
$24,483
@ $76.99 · 2024-09-03
KLINGER SHANNON THYME
Officer
$8,777
@ $76.99 · 2024-09-03
MOCK JAMES M
Chief Financial Officer
$12,640
@ $78.02 · 2024-08-29
HOGE STEPHEN
President
$23,408
@ $78.03 · 2024-08-29
KLINGER SHANNON THYME
Officer
$12,640
@ $78.02 · 2024-08-29
MOCK JAMES M
Chief Financial Officer
$104,881
@ $79.40 · 2024-08-28
KLINGER SHANNON THYME
Officer
$104,722
@ $79.39 · 2024-08-28
HOGE STEPHEN
President
$21,363
@ $84.11 · 2024-08-12
AFEYAN NOUBAR BOGHOS
Director
$1.80M
@ $119.96 · 2024-07-31
AFEYAN NOUBAR BOGHOS
Director
$1.77M
@ $117.80 · 2024-07-24
AFEYAN NOUBAR BOGHOS
Director
$1.84M
@ $122.84 · 2024-07-17
HOGE STEPHEN
President
$1.82M
@ $121.12 · 2024-07-15
AFEYAN NOUBAR BOGHOS
Director
$1.76M
@ $117.08 · 2024-07-10
MOCK JAMES M
Chief Financial Officer
$81,465
@ $118.24 · 2024-07-08
AFEYAN NOUBAR BOGHOS
Director
$1.91M
@ $127.22 · 2024-06-26
AFEYAN NOUBAR BOGHOS
Director
$2.00M
@ $133.57 · 2024-06-18
HOGE STEPHEN
President
$2.07M
@ $138.16 · 2024-06-17
AFEYAN NOUBAR BOGHOS
Director
$2.21M
@ $147.20 · 2024-06-12
KLINGER SHANNON THYME
Officer
$766,785
@ $148.09 · 2024-06-10
AFEYAN NOUBAR BOGHOS
Director
$2.27M
@ $151.25 · 2024-06-05
MOCK JAMES M
Chief Financial Officer
$97,237
@ $140.72 · 2024-06-03
HOGE STEPHEN
President
$47,704
@ $140.72 · 2024-06-03
KLINGER SHANNON THYME
Officer
$17,168
@ $140.72 · 2024-06-03
MOCK JAMES M
Chief Financial Officer
$26,444
@ $144.50 · 2024-05-29
HOGE STEPHEN
President
$49,276
@ $144.50 · 2024-05-29
KLINGER SHANNON THYME
Officer
$26,444
@ $144.50 · 2024-05-29
AFEYAN NOUBAR BOGHOS
Director
$2.90M
@ $145.08 · 2024-05-29
KLINGER SHANNON THYME
Officer
$210,566
@ $162.47 · 2024-05-28
MOCK JAMES M
Chief Financial Officer
$105,283
@ $162.47 · 2024-05-28
AFEYAN NOUBAR BOGHOS
Director
$2.36M
@ $157.57 · 2024-05-22
HOGE STEPHEN
President
$1.91M
@ $127.49 · 2024-05-15
AFEYAN NOUBAR BOGHOS
Director
$1.91M
@ $127.32 · 2024-05-15
HOGE STEPHEN
President
$30,844
@ $120.96 · 2024-05-10
AFEYAN NOUBAR BOGHOS
Director
$1.83M
@ $121.68 · 2024-05-08
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.
🎭 Mr. Market's Mood
Learn more →ABBV
😐Neutral(52/100)
"Market is pricing this stock without strong emotion in either direction"
Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
MRNA
😨Fear(35/100)
"Market is pessimistic — investigate whether fears are temporary or structural"
Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
⚖️ Buffett Signal
Learn more →ABBV
⚪Awaiting DCF Data
The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.
DCF Margin of Safety: N/AMr. Market's Mood: Neutral (52)
MRNA
⚪Awaiting DCF Data
The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.
DCF Margin of Safety: N/AMr. Market's Mood: Fear (35)